RESUMO
Sixteen novel mononuclear Cu(II), Co(II), Zn(II), and Ni(II) complexes of the biologically active ligand clotrimazole (clotri) of the forms [M(clotri)(2)Cl(2)]·nH(2)O (1-4), [M(clotri)(2)Br(2)]·nH(2)O (5-7), [M(clotri)(3)Br(2)] (8), [M(clotri)(3)NO(3)]NO(3)·nH(2)O (9, 11), [M(clotri)(3)(NO(3))(2)]·nH(2)O (10), and [M(clotri)(3)(OH(2))(2)NO(3)]NO(3)·nH(2)O (12) were synthesized and fully characterized. Dinuclear [Cu(2)(clotri)(4)µ(2)-Cl(4)]·2H(2)O (1a) and [Cu(2)(clotri)(4)µ(2)-Br(2)]·2H(2)O (5b) as well as tetranuclear [Cu(4)(clotri)(4)µ(4)-Br(6)µ(4)-O] (5a) complexes were also isolated. Complexes 1-7, 9, and 11 present a tetrahedral geometry; complex 8 exhibits a pentacoordinated structure; complexes 1a, 10 and 12 an octahedral geometry. X-ray crystal structures of [Cu(clotri)(2)Cl(2)](1), [Cu(clotri)(2)(EtOH)Cl(2)](1·EtOH), [Zn(clotri)(2)Cl(2)] (3), [Zn(clotri)(2)Br(2)] (7), and [Cu(4)(clotri)(4)µ(4)-Br(6)µ(4)-O] (5a) were obtained. Complexes 1-12 were tested for cytotoxic activity against the human carcinoma cell lines HeLa (cervix-uterine), PC3 (prostate), and HCT-15 (colon) displaying IC(50) values <30 µM. Confocal microscopy and nuclear dying (DAPI) for complex 1 showed condensation of cromatin and nuclear membrane fragmentation. Immunocytochemical detection/expression of biomarkers suggests that complexes 1 and 9 induce cell death via apoptosis. TUNEL assay detected DNA fragmentation in HeLa cells, resulting from apoptotic signaling cascades induced by Cu(II) complexes 1 and 9. (1)H NMR studies of the Zn(II) complexes showed that they can bind to nucleotides.
Assuntos
Antineoplásicos/síntese química , Clotrimazol/química , Cobalto/química , Complexos de Coordenação/síntese química , Cobre/química , Níquel/química , Zinco/química , Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Linhagem Celular Tumoral , Complexos de Coordenação/farmacologia , Cristalografia por Raios X , Fragmentação do DNA/efeitos dos fármacos , Expressão Gênica/efeitos dos fármacos , Humanos , Ligantes , Espectroscopia de Ressonância Magnética , Microscopia Confocal , Modelos Moleculares , Estrutura MolecularRESUMO
PURPOSE: Pathologic angiogenesis has been correlated with tumor growth, dissemination, metastasis, and prognosis in solid tumors including breast cancer. Angiogenesis has also been implicated in the pathophysiology of, and shown to be a therapeutic target in tumors arising in the bone marrow. The status of angiogenesis in the bone marrow of breast cancer patients is unknown. The aim of this study was to estimate the extent of bone marrow angiogenesis in this subset of patients. EXPERIMENTAL DESIGN: We studied 42 women with breast cancer in whom a bone marrow biopsy was done. Bone marrow samples were sorted according to their infiltration status by breast cancer cells. In all bone marrow sections, blood vessels were highlighted by staining endothelial cells with an antibody directed against the CD34-related antigen. A hematopathologist blind to the status of infiltration of breast cancer did the bone marrow vessel count. RESULTS: Nineteen patients (45%) had bone marrow metastasis. The bone marrow microvessel density was significantly higher in patients with bone marrow metastases compared with patients without bone marrow metastases (P < 0.0005). Median bone marrow microvessel density was 2 for the negative bone marrow group, and 15 for the positive bone marrow group. An increased microvessel density was correlated with presence of disease at last follow-up. CONCLUSIONS: This is the first study showing that bone marrow microvessel density is significantly higher in breast cancer patients with bone marrow metastases, when compared with breast cancer patients without evidence of bone marrow metastatic disease. Further research is needed to shed light into the prognostic and therapeutic relevance of this finding.
Assuntos
Medula Óssea/patologia , Neoplasias da Mama/patologia , Neovascularização Patológica , Adulto , Antígenos CD34/biossíntese , Células da Medula Óssea/citologia , Células da Medula Óssea/metabolismo , Células da Medula Óssea/patologia , Neoplasias da Mama/metabolismo , Diferenciação Celular , Proliferação de Células , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Metástase Linfática , Microcirculação , Pessoa de Meia-Idade , Metástase Neoplásica , Razão de Chances , PrognósticoRESUMO
We have proposed that controlled peroxidative modifications of membranes could be playing a role in the early steps of liver regeneration. Hence, lipid peroxidation (LP) was modified in vivo by treatment with vitamin E in rats subjected to partial hepatectomy (PH), and its influence on liver regeneration was evaluated. Our results, using several methods to monitor LP, indicate that vitamin E administration promoted a decreased LP rate in liver subcellular membranes. Vitamin E drastically diminished cytosolic LP, shifting earlier increased LP in plasma membranes, and promoted a higher increase of nuclear LP in animals subjected to PH. Pretreatment with vitamin E induced a striking reduction of liver mass recovery and nuclear bromodeoxyuridine labeling (clearly shown at 24 hours after surgery), as well as promoted a decreased expression of cyclin D1 and of the proliferating cell nuclear antigen after PH. These effects seem to lead to a decreased mitotic index at 48 hours after PH. Vitamin E pretreatment also diminished PH-induced hypoglycemia but elevated serum bilirubin level, which was not observed in PH animals without vitamin treatment. In conclusion, an enhanced but controlled LP seems to play a critical role during the early phases of liver regeneration. Decreasing magnitude or time course of the PH-promoted enhanced LP (at early post-PH stages) by in vivo treatment with vitamin E could promote an early termination of preparative cell events, which lead to the replicative phase, during PH-promoted liver proliferation. The latter could have a significant implication in the antitumorigenic effect ascribed to the treatment with vitamin E.
Assuntos
Peroxidação de Lipídeos , Regeneração Hepática/efeitos dos fármacos , Fígado/efeitos dos fármacos , alfa-Tocoferol/farmacologia , Administração Oral , Animais , Bilirrubina/sangue , Bromodesoxiuridina/metabolismo , Fracionamento Celular , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , DNA/biossíntese , Hepatectomia , Técnicas Imunoenzimáticas , Membranas Intracelulares/efeitos dos fármacos , Membranas Intracelulares/metabolismo , Peróxidos Lipídicos/antagonistas & inibidores , Fígado/metabolismo , Fígado/patologia , Regeneração Hepática/fisiologia , Masculino , Índice Mitótico , Antígeno Nuclear de Célula em Proliferação/metabolismo , Ratos , Ratos Wistar , alfa-Tocoferol/administração & dosagemRESUMO
Objetivo. Evaluar las diferencias entre pacientes con cáncer de mama sobrevivientes y fallecidas, todas ellas en etapa IV y con metástasis supraclavicular o en axila contralateral al ingreso, con el propósito de identificar los factores que se asociaron a la sobrevida. Métodos. De los expedientes de 13 años (1975-88) se obtuvieron dos grupos de 10 pacientes cada uno: el grupo 1 fue de pacientes vivas sin actividad tumoral y sobrevida mayor a cinco años; el grupo 2 tuvo una sobrevida menor a cinco años y fallecieron por el tumor. En ambos grupos se evaluaron datos clínicos (edad, estado menstrual y tiempo de evolución). Además, se revisaron los factores pronósticos histológicos como tamaño tumoral, estado ganglionar, porcentaje de fibrosis e infiltrado inflamatorio, grado nuclear y necrosis, y se realizaron estudios inmunohistoquímicos de CD34 para angiogénesis, catepsina D, antioncogén p53, oncogén c-erb B2, factor de crecimiento epidérmico, receptores de estrógeno y progesterona y cinética celular; se analizaron curvas de sobrevida en los parámetros que mostraron diferencias intergrupos. Resultados. Los factores asociados a mayor sobrevida fueron: infiltrado inflamatorio escaso (p=0.001), fibrosis escasa (p=0.07), menor expresión de p53 (p=0.03) y tener receptores para estrógenos (p=0.03); hubo otros factores marginales: tener menor de 6 ganglios positivos (p=0.007), y tener receptor de progesterona (p=0.07)